{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:25:45Z","timestamp":1770989145629,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12013-012-9353-2","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T08:07:59Z","timestamp":1333526879000},"page":"159-169","source":"Crossref","is-referenced-by-count":22,"title":["Cryotherapy is Associated with Improved Clinical Outcomes of Sorafenib Therapy for Advanced Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"63","author":[{"given":"Yongping","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjing","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,5]]},"reference":[{"key":"9353_CR1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","volume":"2","author":"DM Parkin","year":"2001","unstructured":"Parkin, D. M. (2001). Global cancer statistics in the year 2000. Lancet Oncology, 2, 533\u2013543.","journal-title":"Lancet Oncology"},{"key":"9353_CR2","first-page":"1","volume":"29","author":"T Zhaoyou","year":"2009","unstructured":"Zhaoyou, T. (2009). Perspective of clinical oncology from the viewpoint of liver cancer studies. Tumor (China), 29, 1\u20134.","journal-title":"Tumor (China)"},{"key":"9353_CR3","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2003.11.137","volume":"21","author":"HY Yoo","year":"2003","unstructured":"Yoo, H. Y., Patt, C. H., Geschwind, J. F., et al. (2003). The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-Year survival has improved significantly with time. Journal of Clinical Oncology, 21, 4329\u20134335.","journal-title":"Journal of Clinical Oncology"},{"key":"9353_CR4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","volume":"347","author":"HI Yang","year":"2002","unstructured":"Yang, H. I., Lu, S. N., Liaw, Y. F., et al. (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma. The New England Journal of Medicine, 347, 168\u2013174.","journal-title":"The New England Journal of Medicine"},{"key":"9353_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2005-871194","volume":"25","author":"M Sherman","year":"2005","unstructured":"Sherman, M. (2005). Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Seminars in Liver Disease, 25, 143\u2013154.","journal-title":"Seminars in Liver Disease"},{"key":"9353_CR6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet, J. M., Burroughs, A., & Bruix, J. (2003). Hepatocellular carcinoma. Lancet, 362, 1907\u20131917.","journal-title":"Lancet"},{"key":"9353_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet, J. M., Burroughs, A., & Bruix, J. (1999). Prognosis of hepatocellular carcinoma: The BCLC staging classification. Seminars in Liver Disease, 19, 329\u2013338.","journal-title":"Seminars in Liver Disease"},{"key":"9353_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/jhep.2002.32089","volume":"35","author":"J Bruix","year":"2002","unstructured":"Bruix, J., & Llovet, J. M. (2002). Prognosis prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 35, 519\u2013524.","journal-title":"Hepatology"},{"key":"9353_CR9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix, J., & Sherman, M. (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208\u20131236.","journal-title":"Hepatology"},{"key":"9353_CR10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1746.2007.05112.x","volume":"23","author":"KW Park","year":"2008","unstructured":"Park, K. W., Park, J. W., et al. (2008). Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. Journal of Gastroenterology and Hepatology, 23, 467\u2013473.","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"9353_CR11","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/lt.20034","volume":"10","author":"JM Llovet","year":"2004","unstructured":"Llovet, J. M., Fuster, J., Bruix, J., & Barcelona-Clinic Liver Cancer Group. (2004). The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplantation, 10, S115\u2013S120.","journal-title":"Liver Transplantation"},{"key":"9353_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L., Kang, Y. K., Chen, Z., et al. (2009). Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Lancet Oncology, 10, 25\u201334.","journal-title":"Lancet Oncology"},{"key":"9353_CR13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M., Ricci, S., Mazzaferro, V., SHARP Investigators Study Group, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 359, 378\u2013390.","journal-title":"The New England Journal of Medicine"},{"key":"9353_CR14","first-page":"779","volume":"2","author":"J Furuse","year":"2008","unstructured":"Furuse, J. (2008). Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics, 2, 779\u2013788.","journal-title":"Biologics"},{"key":"9353_CR15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1148\/radiol.2442061005","volume":"244","author":"A Hakim\u00e9","year":"2007","unstructured":"Hakim\u00e9, A., Hines-Peralta, A., Peddi, H., et al. (2007). Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: Study in mice. Radiology, 244, 464\u2013470.","journal-title":"Radiology"},{"key":"9353_CR16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1148\/radiol.2431052133","volume":"243","author":"TD Atwell","year":"2007","unstructured":"Atwell, T. D., Farrell, M. A., Callstrom, M. R., et al. (2007). Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: Initial experience. Radiology, 243, 276\u2013283.","journal-title":"Radiology"},{"key":"9353_CR17","first-page":"554","volume":"4","author":"W Jungraithmayr","year":"2005","unstructured":"Jungraithmayr, W., Burger, D., Olschewski, M., & Eggstein, S. (2005). Cryoablation of malignant liver tumor: Results of a single center study. Hepatobiliary & Pancreatic Diseases International, 4, 554\u2013560.","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"key":"9353_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R., & Llovet, J. M. (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Diseases, 30, 52\u201360.","journal-title":"Seminars in Liver Diseases"},{"key":"9353_CR19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti, A., Colevas, A. D., Setser, A., et al. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13, 176\u2013181.","journal-title":"Seminars in Radiation Oncology"},{"key":"9353_CR20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10585-009-9283-6","volume":"26","author":"C Wang","year":"2009","unstructured":"Wang, C., Lu, Y., Chen, Y., et al. (2009). Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon\u2013helium cryoablation: A prospective study. Clinical Experimental Metastasis, 26, 839\u2013848.","journal-title":"Clinical Experimental Metastasis"},{"key":"9353_CR21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2007-01-068031","volume":"110","author":"DM Kuang","year":"2007","unstructured":"Kuang, D. M., Wu, Y., Chen, N., Cheng, J., Zhuang, S. M., & Zheng, L. (2007). Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood, 110, 587\u2013595.","journal-title":"Blood"},{"key":"9353_CR22","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1200\/JCO.2002.07.089","volume":"20","author":"RT Poon","year":"2002","unstructured":"Poon, R. T., Ng, I. O., Lau, C., et al. (2002). Tumor microvessel density as a predictor recurrence after resection of hepatocellular carcinoma: A prospective study. Journal of Clinical Oncology, 20, 1775\u20131785.","journal-title":"Journal of Clinical Oncology"},{"key":"9353_CR23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1478-3231.2008.01916.x","volume":"29","author":"T Yau","year":"2009","unstructured":"Yau, T., Chan, P., Epstain, R., & Poon, R. T. P. (2009). Management of advanced hepatocellular carcinoma in era of target therapy. Liver International, 29, 10\u201317.","journal-title":"Liver International"},{"key":"9353_CR24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","volume":"115","author":"T Yau","year":"2009","unstructured":"Yau, T., Chan, P., Ng, K. K., et al. (2009). Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response. Cancer, 115, 428\u2013436.","journal-title":"Cancer"},{"key":"9353_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6604784","volume":"100","author":"TF Greten","year":"2009","unstructured":"Greten, T. F., Korangy, F., Manns, M. P., & Malek, N. P. (2009). Molecular therapy for the treatment of hepatocellular carcinoma. British Journal of Cancer, 100, 19\u201323.","journal-title":"British Journal of Cancer"},{"key":"9353_CR26","doi-asserted-by":"crossref","unstructured":"Zuro, L. M., & Staren, E. D. (1996). Cryosurgical ablation of unresectable hepatic tumors. Association of perioperative Registered Nurses (AORN) Journal, 64, 231\u2013236, 239\u2013244.","DOI":"10.1016\/S0001-2092(06)63151-7"},{"key":"9353_CR27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00534-009-0124-4","volume":"16","author":"T Shimizu","year":"2009","unstructured":"Shimizu, T., Sakuhara, Y., Abo, D., et al. (2009). Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. Journal of Hepatobiliary & Pancreatic Surgery, 16, 816\u2013823.","journal-title":"Journal of Hepatobiliary & Pancreatic Surgery"},{"key":"9353_CR28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jso.20712","volume":"95","author":"S Osada","year":"2007","unstructured":"Osada, S., Imai, H., Tomita, H., et al. (2007). Serum cytokine levels in response to hepatic cryoablation. Journal of Surgical Oncology, 95, 491\u2013498.","journal-title":"Journal of Surgical Oncology"},{"key":"9353_CR29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00432-008-0496-x","volume":"135","author":"JH Shim","year":"2009","unstructured":"Shim, J. H., Park, J. W., Choi, J. I., Park, B. J., & Kim, C. M. (2009). Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. Journal of Cancer Research and Clinical Oncology, 135, 617\u2013625.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"9353_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","volume":"14","author":"M Pinter","year":"2009","unstructured":"Pinter, M., Sieghart, W., Ivo Graziadei, I., et al. (2009). Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. The Oncologist, 14, 70\u201376.","journal-title":"The Oncologist"},{"key":"9353_CR31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","volume":"14","author":"RC Kane","year":"2009","unstructured":"Kane, R. C., Farrell, A. T., Madabushi, R., et al. (2009). Sorafenib for the treatment of unresectable hepatocellular carcinoma. The Oncologist, 14, 95\u2013100.","journal-title":"The Oncologist"},{"key":"9353_CR32","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.299.14.1669","volume":"299","author":"BQ Cheng","year":"2008","unstructured":"Cheng, B. Q., Jia, C. Q., Liu, C. T., et al. (2008). Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3\u00a0cm: A randomized controlled trial. Journal of the American Medical Association, 299, 1669\u20131677.","journal-title":"Journal of the American Medical Association"},{"key":"9353_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse, J., Ishii, H., Nakachi, K., et al. (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Science, 99, 159\u2013165.","journal-title":"Cancer Science"},{"key":"9353_CR34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","volume":"43","author":"MA W\u00f6rns","year":"2009","unstructured":"W\u00f6rns, M. A., Weinmann, A., Pfingst, K., et al. (2009). Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Journal of Clinical Gastroenterology, 43, 489\u2013495.","journal-title":"Journal of Clinical Gastroenterology"},{"key":"9353_CR35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","volume":"15","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi, B., Santini, D., Russo, A., et al. (2010). Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 15, 85\u201392.","journal-title":"Oncologist"},{"key":"9353_CR36","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","volume":"103","author":"C Schramm","year":"2008","unstructured":"Schramm, C., Schuch, G., & Lohse, A. W. (2008). Sorafenib-induced liver failure. American Journal of Gastroenterology, 103, 2162\u20132163.","journal-title":"American Journal of Gastroenterology"},{"key":"9353_CR37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","volume":"41","author":"D Semela","year":"2004","unstructured":"Semela, D., & Dufour, J. F. (2004). Angiogenesis and hepatocellular carcinoma. Journal of Hepatology, 41, 864\u2013880.","journal-title":"Journal of Hepatology"},{"key":"9353_CR38","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu, L., Cao, Y., Chen, C., et al. (2006). Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Research, 66, 11851\u201311858.","journal-title":"Cancer Research"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12013-012-9353-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T19:26:08Z","timestamp":1713813968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12013-012-9353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9353"],"URL":"https:\/\/doi.org\/10.1007\/s12013-012-9353-2","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]}}}